Venous%20thromboembolism%20-%20management News

News

DOACs, VKAs show similar efficacy, safety for VTE in octogenarians

Audrey Abella, 20230301100000

In an international multi-database cohort study, direct oral anticoagulants (DOACs) demonstrated comparable efficacy and safety with vitamin K antagonists (VKAs) for octogenarians with venous thromboembolism (VTE).

DOACs on par with VKAs in octogenarians with VTE

20230114110000

Direct oral anticoagulants (DOACs) are as effective and safe as vitamin K antagonists (VKAs) among octogenarians with venous thromboembolism (VTE), a study has shown.

Edoxaban prevents thromboembolism in children with cardiac disease

20230104110000

Edoxaban may be used as an alternative treatment for thromboembolism (TE) prevention in children with cardiac disease showing low rates of clinically relevant bleeding and TE, suggests a study. Some of its advantages include once-daily dosing and infrequent monitoring requirement.

Pemafibrate reduces triglycerides, but not CV events, in patients with T2D, hypertriglyceridemia

Roshini Claire Anthony, 20221223180001

Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.

Rivaroxaban + aspirin combo halves stroke risk in COMPASS

3-month rivaroxaban use safe, effective in isolated DVT

Stephen Padilla, 20221201120000

Treatment with rivaroxaban for 3 months leads to a safe and successful reduction of recurrent venous thromboembolism (VTE) risk compared to treatment for 6 weeks in patients with isolated distal deep vein thrombosis (DVT), a study has shown.

Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?

Roshini Claire Anthony, 20221023100001

A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.

Multimodal thrombectomy device holds promise in DVT treatment

Stephen Padilla, 20221017120000

A novel thrombectomy device using a sequestered approach delivers positive clinical outcomes in the treatment of high-risk, large-volume deep vein thrombosis (DVT), according to a study.

Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery

Stephen Padilla, 20220929120000

Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.

Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?

20220927130000

Some men who undergo artificial urinary sphincter (AUS) and inflatable penile prosthesis (IPP) surgery encounter a venous thromboembolism (VTE) event within 90 days of their operation, reports a study.

Heparin dose may not affect antepartum VTE incidence

VTE prevention in pregnancy: Does heparin dose matter?

Roshini Claire Anthony, 20220802180001

In pregnant women with a history of venous thromboembolism (VTE), receipt of low-molecular-weight heparin (LMWH) at either a weight-adjusted intermediate-dose or fixed low-dose during the antepartum and postpartum periods results in similar VTE incidence, according to findings of the Highlow study. However, there was a numerically lower incidence of VTE during the postpartum period with intermediate-dose LMWH.

Product Highlight - COSYREL

16 Sep 2020

COSYREL – Bisoprolol fumarate, perindopril arginine 5 mg/5 mg, 5 mg/10 mg and 10 mg/10 mg FC tab

Personalizing treatment for chronic angina with concomitant diseases

23 Dec 2019

At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.

NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?

02 Nov 2021

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]